Indaptus Therapeutics Appoints Yu Ding as CFO and Qinglai Lu to Board of Directors

On March 31, 2026, Indaptus Therapeutics, Inc. announced a series of leadership changes. Nir Sassi resigned as Chief Financial Officer effective April 1, 2026, with the company noting the departure was not due to any disagreements regarding operations or practices. To succeed him, the Board appointed Yu Ding as the new Chief Financial Officer, effective April 1, 2026. Yu Ding brings over 20 years of financial executive experience, having previously served as CFO of Grand Auto Service Group Co., Ltd. and Grand Baoxin Auto Group Limited. Additionally, the Board appointed Qinglai Lu as an independent director, effective April 8, 2026. Mr. Lu, a Managing Partner at Plunkett Capital and former Goldman Sachs executive, will also join the Audit Committee along with Jerome Jabbour. These committee appointments follow the resignation of Matthew McMurdo from the Audit Committee. The leadership transition aims to leverage the extensive international financial and capital markets expertise of the new appointees.